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ABSTRACT
Pyoderma gangrenosum (PG) is an auto inflammatory non-infectious neutrophilic dermatosis often 
presenting with pustules or nodules that progress to ulcers. PG has specific clinical features and non-
characteristic histology findings. Some systemic diseases such as Crohn’s disease, ulcerative colitis, 
rheumatoid arthritis, hematologic malignancy or autoimmune disease are commonly associated with PG. 
One of the most characteristic features of pyoderma gangrenosum is pathergy, which is the appearance of 
new lesions at sites of trauma, including surgical wounds.
We present a 62-year-old male with a large ulceration on the left lower leg after a bee sting.
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INTRODUCTION
Pyoderma gangrenosum (PG) is a rare inflam-
matory neutrophilic dermatosis of unknown etiol-
ogy. It may be associated with a coexisting system-
ic disease, most commonly Crohn’s disease, ulcer-
ative colitis, rheumatoid arthritis, hematologic ma-
lignancy or autoimmune disease (1,2). In most of the 
cases the initial lesion is a papule, pustule, or nod-
ule appearing after minor trauma, that progresses 
to painful, slowly growing ulcer. It is often misdiag-
nosed as a soft tissue infection that can coincidental-
ly improve due to the systemic antibiotic therapy and 
wound care (1,2,3).
We present a case of pyoderma gangrenosum 
persisting for 7 months, not associated with system-
ic disease.
CASE REPORT
A 62-year-old male presented to a dermatology 
clinic in 2019 with a history of bee sting after which 
a non-healing painful ulcer developed on the antero-
medial aspect of the left shin. The lesion was large 
and deep, with a diameter of 15/20 cm, elevated bor-
ders and erythematous periphery (Fig. 1, Fig. 2).
Previously, the patient was treated with local 
antiseptic, proteolytic enzyme and a systemic antibi-
otic with unsatisfactory improvement.
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of a sample taken from the ulcer found Pseudomonas 
aeruginosa.
Doppler ultrasound of the leg, chest X-ray, gas-
tro-, colonoscopy and abdominal ultrasound of the 
patient found no significant abnormalities.
A hematologist and a gastroenterologist were 
consulted and they recommended treatment with fo-
lic acid, vit. B6, vit. B12 and ursodeoxycholic acid.
Skin biopsy from the border of the lesion was 
performed. The histologic findings are: pseudoepi-
theliomatous hyperplasia with intraepidermal neu-
trophilic abscesses and spongiosis of the epidermis. 
In the dermis diffuse inflammatory infiltrate con-
taining numerous neutrophils was observed (Fig. 3, 
Fig. 4, Fig. 5).
The clinical course with pathergic phenome-
non, unresponsiveness to antibiotic therapy and his-
topathologic features of sterile neutrophilic infiltra-
tion led to diagnosis pyoderma gangrenosum.
Systemic therapy with ciprofloxacin 200 mg 
twice daily, 6-methylprednisolone 40 mg i.v., diami-
nodiphenyl sulfone (DDS) 50 mg twice daily and 
The laboratory tests showed: erythrocytes 
(RBC) – 3.03 10 1̂2/l; erythroblasts – 10^9/L; hemo-
globin (HGB) – 118.0 g/L ; hematocrit (HCT) – 0.326 
l/l ; MCV – 107.7 fl; MCH – 39.0 pg; MCHC – 362.0 
g/L; granulocytes (Gran) % - 77.6%; lymphocytes 
(Lym) % - 15.0%; iron binding capacity (IBC) – 40.3 
µmol/L; gamma-glutamyl transferase (GGT) – 94.0 
U/L; procalcitonin – 0.4249 ng/mL; hsCRP – 70.4 
mg/L; ferritin – 365.58 ng/mL; bilirubin total – 12.9 
µmol/L; bilirubin direct – 4.8 µmol/L. Urine tests: 
blood ++ ; ketone bodies (+); urobilinogen ++; biliru-
bin +++; leucocytes – neg. Microbiology culture test 
Fig. 1. Initial clinical findings
Fig. 2. Initial clinical findings (closer look)
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esomeprazole was initiated. Locally, KMnO4 com-
presses were applied.
Clinical improvement was observed in the first 
10 days of the therapeutic regimen. Significant part 
of the devitalized tissue was removed. The size and 
the depth of the ulcer decreased. There were no signs 
of bacterial contamination (Fig. 6). 
DISCUSSION
Pyoderma gangrenosum (PG) is a neutrophil-
ic dermatosis, with characteristic clinical and non-
characteristic histology findings, first described by 
Brocq et al. in 1916 as “phagedenisme geometrique/
geometric phagedenism” (2,3,4). Although the etio-
pathogenesis of PG is still unclear, there are in-
creasing evidence that it shares common pathogen-
ic mechanisms with other autoimmune disorders 
(5,6,7). Neutrophilic dysfunction, systemic inflam-
mation, and associated genetic factors are all in-
volved in the formation of PG ulcers (8,9).
Previously, there were no clinical criteria distin-
guishing PG from necrotizing soft tissue infections 
(10). Recently, E. Maverakis et al. suggested one ma-
jor and 4 of 8 minor criteria that can be used to diag-
nose PG with high specificity (11). The major criteri-
on is biopsy of an ulcer edge demonstrating neutro-
philic infiltrate and the 8 minor criteria are: (1) ex-
clusion of infection; (2) pathergy; (3) history of in-
flammatory bowel disease or inflammatory arthri-
tis; (4) history of papule, pustule, or vesicle ulcerat-
ing within 4 days of appearing; (5) peripheral erythe-
ma, undermining border, and tenderness at ulcer-
ation site; (6) multiple ulcerations, at least 1 on an an-
Fig. 3. Histologic findings, magnification x40
Fig. 4. Histologic findings, magnification x100
Fig. 5. Histologic findings, magnification x200
Fig. 6. Clinical improvement observed after 10 days of 
therapy
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terior lower leg; (7) cribriform or “wrinkled paper” 
scar(s) at healed ulcer sites; and (8) decreased ulcer 
size within 1 month of initiating immunosuppressive 
medication(s) (11). Applying those criteria yields 86% 
to 90% specificity and sensitivity.
The presented case showed: typical histopa-
thology findings, pathergy, erythematous periph-
ery of the ulcer, typical anterior shin localization and 
therapeutic effectiveness of the immunosuppressive 
treatment. 
Pathergy is an important sign supporting the 
diagnosis of PG (12,13). It is defined as development 
of skin lesions that resist healing after minor tissue 
trauma as in our case. The lesion classically begins 
as a pustule, vesicle, or nodule that rapidly progress-
es into a painful ulcer or erosion with raised borders 
(14,15). That type of lesions can heal spontaneous-
ly or coincidentally with antibiotic treatment. Often 
patients believe they have been bitten by a spider or 
other type of insect (16). Early aggressive tissue de-
bridement can worsen the therapy response due to 
pathergy phenomenon.
 The clinical course of PG is not predictable, 
therefore the treatment should be individualized 
(17). Differential diagnosis of PG includes infectious 
(atypical mycobacterial ulcers, cutaneous tuberculo-
sis, cutaneous leishmaniasis, sporotrichosis, ecthyma 
gangrenosum, syphilis) and noninfectious diseases 
(vasculitis, cutaneous malignancies, drug-induced 
conditions) (18). Skin biopsy and microbiology tests 
are crucial for the diagnosis. In the presented case 
differential diagnosis with ecthyma gangrenosum is 
important, because of the presence of Pseudomonas 
aeruginosa in the microbial culture test. The typical 
massive neutrophilic infiltrate confirms the diagno-
sis of PG (in contrast, the histopathology of ecthyma 
gangrenosum shows vascular necrosis with few in-
flammatory cells). We would interpret the presence 
of Pseudomonas aeruginosa as contamination of a 
preexisting PG lesion, which is common for cases of 
ulcers with prolonged healing. 
The treatment of PG remains challenging. 
Thorough physical examination and comorbidity in-
vestigation are crucial for the precise diagnosis and 
treatment of PG. For mild cases high-potency top-
ical steroids, intralesional application of triamcino-
lone acetonide and calcineurin inhibitors are mostly 
used with good therapeutic response (19,20). For se-
vere PG, first-line therapy includes systemic steroids 
or cyclosporine (21). Second-line options are: metho-
trexate, azathioprine, mycophenolate mofetil, cyclo-
phosphamide, dapsone, thalidomide, colchicine and 
intravenous immunoglobulins used to decrease the 
steroid dose in maintenance therapy or in combina-
tion with first-line agents for recalcitrant PG (21). Re-
cently, biological agents are also used for treatment 
of PG (21, 22). TNF-α  inhibitors prescribed for in-
flammatory bowel diseases (Crohn’s disease and ul-
cerative colitis) can also improve PG associated with 
these conditions (23). IL-1 is the key inflammatory 
mediator triggering release of chemokines involved 
in neutrophil recruitment and activation. Anakinra 
and canakinumab are both therapies that block IL-1 
and have been used to treat refractory PG (24). New 
clinical trials show that biologic agents could be an 
alternative for treatment of severe and refractory PG 
cases (25,26). 
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